- Home
- BTE vs EVO Comparison
BTE vs EVO Comparison
Compare BTE & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTE
- EVO
- Stock Information
- Founded
- BTE 1993
- EVO 1993
- Country
- BTE Canada
- EVO Germany
- Employees
- BTE N/A
- EVO N/A
- Industry
- BTE Meat/Poultry/Fish
- EVO Biotechnology: Pharmaceutical Preparations
- Sector
- BTE Consumer Staples
- EVO Health Care
- Exchange
- BTE Nasdaq
- EVO Nasdaq
- Market Cap
- BTE 1.4B
- EVO 1.5B
- IPO Year
- BTE N/A
- EVO 2021
- Fundamental
- Price
- BTE $2.07
- EVO $4.26
- Analyst Decision
- BTE Hold
- EVO Buy
- Analyst Count
- BTE 1
- EVO 2
- Target Price
- BTE $5.50
- EVO $5.90
- AVG Volume (30 Days)
- BTE 34.1M
- EVO 95.8K
- Earning Date
- BTE 07-31-2025
- EVO 08-13-2025
- Dividend Yield
- BTE 3.12%
- EVO N/A
- EPS Growth
- BTE N/A
- EVO N/A
- EPS
- BTE 0.28
- EVO N/A
- Revenue
- BTE $2,327,227,884.00
- EVO $851,944,444.00
- Revenue This Year
- BTE $3.43
- EVO $10.08
- Revenue Next Year
- BTE N/A
- EVO $10.99
- P/E Ratio
- BTE $7.15
- EVO N/A
- Revenue Growth
- BTE 10.55
- EVO 1.50
- 52 Week Low
- BTE $1.36
- EVO $2.84
- 52 Week High
- BTE $3.76
- EVO $5.64
- Technical
- Relative Strength Index (RSI)
- BTE 60.18
- EVO 55.61
- Support Level
- BTE $1.90
- EVO $3.64
- Resistance Level
- BTE $2.15
- EVO $4.36
- Average True Range (ATR)
- BTE 0.10
- EVO 0.09
- MACD
- BTE 0.02
- EVO -0.01
- Stochastic Oscillator
- BTE 77.81
- EVO 86.11
About BTE Baytex Energy Corp
Baytex Energy Corp is an oil and gas company. Geographically, the group operates in Canada and the United States. The company derives a majority of revenue from Canada. Its Canada segment includes the exploration, development, and production of crude oil and natural gas in Western Canada.
About EVO Evotec SE
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.